USPTO serial 98210542
V
Reviewed by CopyMark Law Group
Status 688Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- INNES, ISABEL J
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with V?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $648*
Plus Government fees of $300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Amanda G. Hyland
Amanda G. Hyland Buchalter PC3475 Piedmont Road NESTE 1100Atlanta, GA 30305Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals and biological preparations used in industry and science; chemical and biological reagents for use in industry and science; diagnostic reagents for scientific and research purposes; chemical and biological preparations and reagents for use in diagnostic and analytical tests, including in vitro diagnostic laboratory tests, for scientific purposes and not for medical or veterinary purposes; Reagents for scientific use in the field of life sciences; Active chemical ingredients for use in the manufacture of pharmaceuticals for treating cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); assays for testing stem cell differentiation status, other than for medical or veterinary use | ACTIVE | — |
| 010 | Medical and therapeutic apparatus and instruments for use in treatment of cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS) in humans and animals; Medical and veterinary devices for diagnosing cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs) pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); Medical diagnostic apparatus for analyzing and measuring cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); medical apparatus, instruments and equipment for use in the diagnosis, monitoring and treatment of cancer; medical apparatus, instruments and equipment for use in the monitoring and diagnosis of sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage and inflammation, disorders associated with neutrophil extracellular traps (NETs) and pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); medical apparatus, instruments and equipment for use in monitoring the immune system, namely, for monitoring blood properties; Medical diagnostic apparatus for testing for cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); Medical diagnostic apparatus for use with chemical and biological reagents, for testing for cancer, sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); Medical apparatus for use in carrying out diagnostic assays; Medical apparatus, equipment and instruments for monitoring diseases namely, cancer sepsis, COVID-19, infection, dementia, Alzheimer's disease, transplant-related conditions, thrombosis, vascular damage, inflammation, disorders associated with the immune system, disorders associated with neutrophil extracellular traps (NETs), pneumonia, influenza, acute respiratory distress syndrome (ARDS), septic shock, trauma, organ failure, and multiple organ dysfunction syndrome (MODS); apparatus for DNA and RNA testing for medical purposes; Medical apparatus for use in regeneration of transplant tissues and organs; blood testing apparatus; dialyzers; apheresis devices for medical use; structural parts for all the aforesaid goods | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 29, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 4, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 4, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 29, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 2, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 1, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 1, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 1, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 27, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 27, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 27, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 2, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 2, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 2, 2026 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jan 12, 2026 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jan 12, 2026 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 12, 2026 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 12, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 12, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 12, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 6, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 6, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 6, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 15, 2025 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jan 14, 2025 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jan 14, 2025 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jan 14, 2025 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Dec 2, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 2, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 2, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 11, 2024 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Sep 11, 2024 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Sep 4, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 4, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 4, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 4, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Sep 4, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jun 24, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 24, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 24, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 23, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 14, 2023 | MDSM | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Oct 13, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 9, 2023 | NWAP | NEW APPLICATION ENTERED | — |